You are here: Industry Insights > Small molecule drugs

News List

Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified? Krebs Qin
March 14, 2025
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
Breakthrough in Research of Small Molecule Drugs against SARS-CoV-2 PharmaSources/Xiaonisha
March 21, 2022
Corona virus disease 2019 (COVID-19) caused by a novel single-stranded RNA coronavirus has swept the world. The International Committee on Taxonomy of Viruses (ICTV) named the virus SARS-CoV-2.
Roche, Jnana sign multi-target collaboration deal for small molecule drugs pharmaceutical-business-review
July 24, 2020
Jnana Therapeutics has signed a multi-target collaboration and license deal worth over $1bn with Roche for the discovery of small molecule drugs for the treatment of immune-mediated and neurological diseases.
Biologics or small molecule drugs for rare disease treatment? It is a question PharmaSources/Miling
July 31, 2019
To both patients and pharmaceutical practitioners, it is a question as to whether to choose biologics or small molecule drugs for rare disease treatment, since the prices are sky-high.
Skyhawk and Takeda partner to develop small molecule drugs pharmaceutical-technology
May 08, 2019
US-based Skyhawk Therapeutics has formed a strategic alliance with Takeda Pharmaceutical to discover and develop small molecule drug candidates for multiple targets across neurodegenerative diseases.
RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D b3cnewswire
July 18, 2017
RedHill Biopharma Ltd. announced that the last patient enrolled in the Phase II study with BEKINDA® (RHB-102)(1) 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) has completed the treatment course and follow-up visit.